Literature DB >> 6866052

Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma.

O Serri, E Rasio, H Beauregard, J Hardy, M Somma.   

Abstract

To assess the long-term prognosis for women with prolactinoma after selective transsphenoidal adenomectomy, we followed 44 patients for 6.2 +/- 1.5 years. Group 1 (28 patients) had microprolactinomas, and Group 2 (16 patients) had macroprolactinomas. After surgery, normal plasma prolactin levels, resumption of menses, and cessation of galactorrhea were observed in 24 Group 1 patients (85 per cent) and 5 Group 2 patients (31 per cent). Hyperprolactinemia recurred in 12 of the 24 Group 1 patients and in 4 of the 5 Group 2 patients after 4 +/- 1.3 and 2.5 +/- 1.6 years of remission, respectively. There was no radiologic evidence of tumor recurrence in any patient, and no relation was found between the occurrence of pregnancy after surgery and the recurrence of hyperprolactinemia. Clinical and biologic features before surgery could not predict the long-term outcome. However, the immediate postoperative level of plasma prolactin was significantly lower in patients in whom normal prolactinemia (6.4 +/- 1.1 ng per milliliter) was maintained than in those who relapsed (11.7 +/- 1.5 ng per milliliter) (P less than 0.02). We conclude that recurrence of hyperprolactinemia after successful surgery is frequent but delayed. The immediate postoperative level of plasma prolactin may be a predictive risk factor.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6866052     DOI: 10.1056/NEJM198308043090505

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  40 in total

1.  Role of transsphenoidal operation in the management of pituitary adenomas with suprasellar extension.

Authors:  O Bynke; J Hillman
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

2.  Microprolactinomas: why requiem for surgery?

Authors:  A Liuzzi; G Oppizzi
Journal:  J Endocrinol Invest       Date:  1996-03       Impact factor: 4.256

3.  Treatment of pituitary macroadenomas secreting PRL, HGH or ACTH with long-acting bromocriptine.

Authors:  I Halperin; M D Rodriguez; C Cardenal; R Casamitjana; M J Martinez Osaba; V Lienas; E Vilardell
Journal:  J Endocrinol Invest       Date:  1987-06       Impact factor: 4.256

4.  Endocrinological differentiation of primary hypothalamic and pituitary disease.

Authors:  E E Müller
Journal:  Acta Neurochir (Wien)       Date:  1985       Impact factor: 2.216

5.  Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors.

Authors:  Odelia Cooper; Adam Mamelak; Serguei Bannykh; John Carmichael; Vivien Bonert; Stephen Lim; Galen Cook-Wiens; Anat Ben-Shlomo
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

Review 6.  Diagnosis and management of hyperprolactinemia.

Authors:  Omar Serri; Constance L Chik; Ehud Ur; Shereen Ezzat
Journal:  CMAJ       Date:  2003-09-16       Impact factor: 8.262

7.  Development of pituitary adenoma in women with hyperprolactinaemia: clinical, endocrine, and radiological characteristics.

Authors:  A E Pontiroli; L Falsetti
Journal:  Br Med J (Clin Res Ed)       Date:  1984-02-18

8.  Immunohistochemical examination of the paraadenomatous "normal" pituitary. An evaluation of prolactin cell hyperplasia.

Authors:  A M Landolt; H Minder
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984

9.  Treatment of prolactinomas with megavoltage radiotherapy.

Authors:  A Grossman; B L Cohen; M Charlesworth; P N Plowman; L H Rees; J A Wass; A E Jones; G M Besser
Journal:  Br Med J (Clin Res Ed)       Date:  1984-04-14

10.  Present status of neurosurgery in the treatment of prolactinomas.

Authors:  R Fahlbusch; M Buchfelder
Journal:  Neurosurg Rev       Date:  1985       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.